无抽搐电休克治疗对精神分裂症患者血清指标及认知功能的影响  

Effect of modified electroconvulsive therapy on serum indicators and cognitive function in patients with schizophrenia

作　　者：李慧 田良辉[1] LI Hui;TIAN Liang-hui(Huangpu District Mental Health Center,Shanghai 200023,China)

机构地区：[1]上海市黄浦区精神卫生中心,200023

出　　处：《中国现代药物应用》2024年第22期43-46,共4页Chinese Journal of Modern Drug Application

基　　金：上海市黄浦区科研项目(项目编号:HLQ202011)。

摘　　要：目的 探讨无抽搐电休克治疗(MECT)对精神分裂症患者血清指标及认知功能的影响。方法 选取100例精神分裂症患者为研究对象,随机分为研究组(入组50例,脱落9例,完成41例)和对照组(入组50例,脱落7例,完成43例)。研究组给予常规药物联合MECT,对照组给予常规药物治疗。对比两组患者治疗前后血清脑源性神经营养因子(BDNF)、白细胞介素-6(IL-6)水平及阳性和阴性症状量表(PANSS)评分、重复性成套神经心理状态测验(RBANS)评分,不良反应发生率。结果 治疗前,两组血清BDNF、IL-6水平及PANSS、RBANS评分对比无显著差异(P>0.05);治疗8周后,两组患者血清BDNF水平均高于治疗前,IL-6水平均低于治疗前,且研究组血清BDNF水平24.56(17.00,34.26) ng/ml明显高于对照组的18.67(14.79,24.56) ng/ml,IL-6水平8.70(2.55,13.17) pg/ml低于对照组的15.87(3.93,24.01) pg/ml(P<0.05)。治疗8周后,两组患者RBANS评分较治疗前明显升高,PANSS评分较治疗前明显降低,且研究组RBANS评分(72.44±4.63)分明显高于对照组的(66.19±9.40)分,PANSS评分(54.88±9.58)分明显低于对照组的(75.02±11.53)分(P<0.05)。研究组不良反应发生率为7.32%,明显低于对照组的25.58%(P<0.05)。结论 MECT可以提高精神分裂症患者的血清BDNF水平,降低IL-6水平,明显改善患者的认知功能,且安全性好。Objective To explore the effect of modified electroconvulsive therapy on serum indicators and cognitive function in patients with schizophrenia.Methods A total of 100 patients with schizophrenia were selected as research subjects and randomly divided into the study group(50 enrolled cases,9 drop-out cases,41 completed cases) and the control group(50 enrolled cases,7 drop-out cases,43 completed cases).The study group was treated with conventional drugs combined with MECT,and the control group was treated with conventional drugs.Patients in both groups were compared in terms of serum levels of brain-derived neurotrophic factor(BDNF),interleukin-6(IL-6),positive and negative symptom scale(PANSS) score and repeatable battery for the assessment of neuropsychological status(RBANS) score before and after treatment,and the incidence of adverse reactions.Results Before treatment,there were no significant differences in serum BDNF,IL-6 levels and PANSS and RBANS scores between the two groups(P>0.05).After 8 weeks of treatment,the serum BDNF level was higher than that before treatment,and IL-6 level was lower than that before treatment;the serum BDNF level of 24.56(17.00,34.26) ng/ml in the study group was significantly higher than 18.67(14.79,24.56) ng/ml in the control group;IL-6 of 8.70(2.55,13.17) pg/ml in the study group was lower than 15.87(3.93,24.01) pg/ml in the control group(P<0.05).After 8 weeks of treatment,RBANS scores were significantly higher and PANSS scores in both groups were significantly lower than those before treatment;RBANS score of(72.44±4.63) points in the study group was significantly higher than(66.19±9.40) points in the control group;PANSS score of(54.88±9.58) points in the study group was significantly lower than(75.02±11.53) points in the control group(P<0.05).The incidence of adverse reactions in the study group was 7.32%,which was significantly lower than 25.58% in the control group(P<0.05).Conclusion MECT can increase serum BDNF level and decrease IL-6level in patients with schizophrenia

关 键 词：无抽搐电休克 精神分裂症 脑源性神经营养因子 炎性因子 认知功能 

分 类 号：R749.3[医药卫生—神经病学与精神病学]